Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions.
Aglaia BioMedical Ventures has made 8 investments, has had 1 exit, which was Merus.
Aglaia has raised a total of $65M in a single venture fund, Aglaia Oncology Fund II. This fund was announced on Sep 18, 2014, and raised a total of $65M.